Share
Save
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Study details:
This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 18 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2023-10-03
Primary completion: 2031-02-22
Study completion finish: 2031-02-22
Study type
TREATMENT
Phase
PHASE4
Trial ID
NCT06057402
Intervention or treatment
DRUG: Elranatamab
Conditions
- • Multiple Myeloma
Find a site
Closest Location:
Epworth Freemasons
Research sites nearby
Select from list below to view details:
Epworth Freemasons
Melbourne, Victoria, Australia
Epworth Hospital
Richmond, Victoria, Australia
Slade Pharmacy
Richmond, Victoria, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Participant Group/Arm | Intervention/Treatment |
---|---|
EXPERIMENTAL: Elranatamab
| DRUG: Elranatamab
|
What is the study measuring?
Primary outcome
Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
---|---|---|
Incidence of nonserious adverse events (AEs) leading to permanent discontinuation | Not Specified | A minimum of 90 days after the last dose of study drug |
Incidence of serious adverse events (SAEs) | Not Specified | A minimum of 90 days after the last dose of study drug |
Secondary outcome
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!